+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07623174

Real-World Study of Fruquintinib Use and Outcomes in Adults with Metastatic Colorectal Cancer in Poland

Led by Takeda · Updated on 2026-09-22

110

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Metastatic colorectal cancer mCRC is a type of cancer that starts in the colon or rectum and has spread to other parts of the body. This cancer can be challenging to treat because it behaves differently in each person, and treatments may stop working over time with increasing side effects. This study aims to evaluate how long adults in Poland with mCRC live without their cancer worsening when treated with fruquintinib, a medicine taken orally designed to slow tumor growth, following at least two prior treatments. Participants in this observational study are adults in Poland receiving fruquintinib as part of routine medical care under a national drug program. The study does not involve administering any additional interventions but observes how fruquintinib is used, including when treatment starts, dose changes, and treatment duration. Participants will be followed for up to 12 months after starting fruquintinib or until death. During the study, researchers will collect data from participants existing medical records to understand their medical history, previous treatments, and quality of life while receiving fruquintinib. The main measure is progression-free survivalhow long the cancer does not worsenover 12 months, with overall survival also tracked. This study will help provide real-world information on treatment patterns and outcomes in adults with mCRC in Poland.

CONDITIONS

Brief Title

A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland

Research Team

T

Takeda Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here